8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 589 participants.

Also called NCT01570686

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 589 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01570686
  • EudraCT 2011-005297-36
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Italy, Puerto Rico, Slovakia, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01570686. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-01-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
Condition
Hypertension
Intervention (Drug)
Aliskiren
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01570686
Content hash
632891c96c24a4f871710f0406f8ad2ffda2acdcb31ef2c517c041d8f69f8013